Programmed Death-Ligand 1 and Programmed Death-Ligand 2 mRNAs Measured Using Closed-System Quantitative Real-Time Polymerase Chain Reaction Are Associated With Outcome and High Negative Predictive Value in Immunotherapy-Treated NSCLC
Aileen I. Fernandez(Yale University), David L. Rimm(Yale University), Niki Gavrielatou(National and Kapodistrian University of Athens), Thazin Nwe Aung(Yale University), Yvonne G. Y. Chan, Jodi Weidler, Vesal Yaghoobi(Yale University), Sandra Martínez-Morilla(Yale University), Leena McCann, Myrto Moutafi(University General Hospital Attikon), Saba Shafi(Ministry of Education of the People's Republic of China), Yalai Bai(Yale University), Ioannis Vathiotis(Yale University), Michael Bates, Roy S. Herbst(Smilow Cancer Hospital)
Cited by 13
Related Papers
Lung Cancer
|New England Journal of Medicine|2008|2.4k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
|Journal of Clinical Oncology|2004|1.7k
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k